Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
Daphne M. V. de Vries–Huizing, Else A. Aalbersberg, Michelle W. J. Versleijen, et al.
Cancer Imaging (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens
Elmira Yazdani, Parham Geramifar, Najme Karamzade-Ziarati, et al.
Diagnostics (2024) Vol. 14, Iss. 2, pp. 181-181
Open Access | Times Cited: 15
Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
Beata Kos‐Kudła, Wanda Fołtyn, Anna Malczewska, et al.
Endokrynologia Polska (2022) Vol. 73, Iss. 3, pp. 387-454
Open Access | Times Cited: 35
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update
Martina Di Franco, Lucia Zanoni, Emilia Fortunati, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 5, pp. 538-550
Open Access | Times Cited: 8
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
Niloefar Ahmadi Bidakhvidi, Karolien Goffin, Jeroen Dekervel, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 129-129
Open Access | Times Cited: 36
Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors
Diletta Calabrò, Giulia Argalia, Valentina Ambrosini
Diagnostics (2020) Vol. 10, Iss. 12, pp. 1059-1059
Open Access | Times Cited: 39
The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
Virginia Liberini, Martin W. Huellner, Séréna Grimaldi, et al.
Diagnostics (2020) Vol. 10, Iss. 12, pp. 1083-1083
Open Access | Times Cited: 37
Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response—AJR Expert Panel Narrative Review
Samuel J. Galgano, Amir Iravani, Lisa Bodei, et al.
American Journal of Roentgenology (2022) Vol. 218, Iss. 5, pp. 767-780
Closed Access | Times Cited: 21
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Leandra Piscopo, Emilia Zampella, Sara Pellegrino, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3483-3483
Open Access | Times Cited: 11
Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
Sejin Ha, Yong-il Kim, Jungsu S. Oh, et al.
EJNMMI Physics (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 4
Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study
Iness Megherbi, Christopher Hoog, Marine Perrier, et al.
EJNMMI Research (2025) Vol. 15, Iss. 1
Open Access
Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET)
Martina Di Franco, Giuseppe Lamberti, Davide Campana, et al.
Seminars in Nuclear Medicine (2025)
Open Access
ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours
Clarisse Dromain, Marie‐Pierre Vullierme, Rodney J. Hicks, et al.
Journal of Neuroendocrinology (2021) Vol. 34, Iss. 3
Open Access | Times Cited: 23
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
Wolfgang Roll, Matthias Weckesser, Robert Seifert, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 12, pp. 4016-4027
Open Access | Times Cited: 19
Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
Luca Urso, Stefano Panareo, Angelo Castello, et al.
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 2009-2009
Open Access | Times Cited: 13
Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
Amit Nautiyal, Sofia Michopoulou, Matthew Guy
Clinical and Translational Imaging (2023) Vol. 12, Iss. 2, pp. 157-175
Closed Access | Times Cited: 7
The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective
Laura Mariën, Odeta Islam, Siddharth Chhajlani, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 12, pp. 1833-1851
Closed Access | Times Cited: 7
Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors
Reut Halperin, Amit Tirosh
JCO Oncology Practice (2024) Vol. 20, Iss. 10, pp. 1401-1409
Closed Access | Times Cited: 2
Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies
Lingaku Lee, Irene Ramos-Álvarez, Robert T. Jensen
Cancers (2022) Vol. 14, Iss. 5, pp. 1250-1250
Open Access | Times Cited: 11
Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise
Mirco Bartolomei, Alfredo Berruti, Massimo Falconi, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2501-2501
Open Access | Times Cited: 11
Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT
Hwan Lee, Sarit T. Kipnis, Remy Niman, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 200-200
Open Access | Times Cited: 6
The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors
Osher Ngo Yung Lee, Kel Vin Tan, Vrijesh Tripathi, et al.
Clinical Nuclear Medicine (2022) Vol. 47, Iss. 9, pp. 781-793
Closed Access | Times Cited: 9
Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms
Amir Iravani, Ashwin Singh Parihar, Timothy Akhurst, et al.
Cancer Imaging (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 8
The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.
Virginia Liberini, Martin Hüllner, Séréna Grimaldi, et al.
(2020)
Open Access | Times Cited: 11
Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?
Mark J C van Treijen, J. M. H. Schoevers, Birthe C. Heeres, et al.
Abdominal Radiology (2022) Vol. 47, Iss. 3, pp. 1071-1081
Closed Access | Times Cited: 7
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers
Grace Kong, Geertje Noë, Cherie Chiang, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top